The absence of government regulation in the US has left pharmaceutical companies free to set their own prices based on a number of market considerations. Historically, these have included not only ingredient, research and development costs, but also advertising, the drug's marginal...

Although the advantages of disseminating health information on the world wide web are well recognized, there has been considerable concern about the quality of online information. There has also been some debate as to whether organizations with a vested interest in a product, such as...

Specialty pharmacy service (SPS) companies are filling a new niche in the expanding role of chronic disease management (DM). These companies distribute expensive biotechnology drugs to patients who have relatively uncommon but very expensive chronic diseases. Although there are considerable...

This article analyses the likely implications for the European pharmaceutical market of 2 European Court rulings (Kohll and Decker) and addresses whether these will contribute to the completion of the single European market. In doing so, the Kohll and Decker cases are discussed and the likely...

Objectives: This study examines the organisational structure of pharmacoeconomics departments in major pharmaceutical and biotechnology companies, the impediments to optimal use of pharmacoeconomic evaluations by companies and the integration of pharmacoeconomic analysis with research and...

The Internet has changed healthcare practice and has just begun to influence pharmaceutical consumers and providers. The Internet firstly affects the pharmaceutical consumer through the five main functions it offers to all consumers of care. These functions are: 1. to provide and distribute...

1. Introduction: Contemporary Strategy and Approaches in Healthcare Policy, Innovation and Digitalization -- 2. Prioritization in health care: The influence of frames on accepting prioritization criterial -- 3. Using pharmacoepidemiologic studies to inform drug policy and spending: a health...

Part I. Value Creation and Managing Intellectual Property in the Life Science Industry -- Chapter 1. Value Creation, Valuation and Business Models in the Pharmaceutical Sector -- Chapter 2. Alternative Licensing Strategies: A Piecewise Deterministic Differential Game -- Chapter 3. Partnership...